Some visit links earn us a commission.
Quick verdict
Medvi is the better pick for most patients on overall scoring. Medvi runs a compounded-semaglutide and tirzepatide model at flat monthly pricing, with no lock-in and rapid intake. Comparable to Henry Meds and Mochi on price; less established clinical depth than Form Health or Knownwell. Best fit for cash-pay patients who want predictable monthly cost with minimal friction.
That said, Hims & Hers wins on specific dimensions. Same-day prescription, no lock-in and brand-name confidence. Hims pivoted to branded-only in March 2026 after settling with Novo Nordisk; compounded semaglutide is closed to new patients. Headline price is $299/mo branded Wegovy injectable (self-pay), plus $149/mo membership.
Side-by-side
| Hims & Hers | Medvi | |
|---|---|---|
| Starts from | $299/mo (incl. medication) | $299/mo (incl. medication) |
| Monthly cost gap | Medvi is $120/mo cheaper than Hims & Hers | |
| Lock-in | Month-to-month | Month-to-month |
| Time to prescription | 1 day | 2 days |
| Consultation type | Asynchronous | Asynchronous |
| Affiliate network | Impact | Direct |
Score by dimension
Scores out of 10, equal-weighted across five dimensions. How we score. The winner of each dimension is highlighted.
| Hims & Hers | Medvi | |
|---|---|---|
| Pricing transparency | 6/10 | 8/10 |
| Cancellation terms | 9/10 | 8/10 |
| Onboarding experience | 9/10 | 7/10 |
| Medication options | 5/10 | 7/10 |
| Member reviews | 6/10 | 9/10 |
When to choose Hims & Hers
Best for fast async onboarding
Patients who want a fast, low-friction async path to a branded GLP-1 prescription with predictable monthly pricing.
Hims & Hers wins on cancellation terms, onboarding experience on the dimensional scoring. The caveat: Patients who wanted Hims's old compounded semaglutide tier or who need insurance-routed branded access. Compounded is closed to new patients. Note also: Settled with Novo Nordisk March 9, 2026 over compounded semaglutide marketing
When to choose Medvi
Best for flat compounded with no lock-in
Cash-pay patients who want flat predictable compounded GLP-1 pricing with no lock-in and same-week onboarding. Strong fit if you've taken GLP-1 before and want a simple ongoing prescription channel.
Medvi wins on pricing transparency, medication options, member reviews and runs $120/mo cheaper than Hims & Hers at the entry tier ($179 vs $299). Over a year that's $1,440 you keep. The caveat: Insurance-pathway shoppers, patients with multiple comorbidities needing clinical depth or anyone wanting branded Wegovy or Zepbound through standard PA. Note also: Compounded GLP-1 carries 503A regulatory exposure; see compounded callout
If cost is your main filter
Medvi is the cheaper monthly: $179 all-in vs $299 for Hims & Hers. That's $120 a month or $1,440a year. The 12-month math matters most if you're planning to maintain on GLP-1 long-term. If you're running a 3-month trial, the $360 delta is small against the cost of stopping early on the wrong dose. Insurance changes the picture: if either program runs prior auth and your plan covers Wegovy or Zepbound, branded with copay can beat both cash-pay totals.
If lock-in is your main filter
Hims & Hers (month-to-month) and Medvi (month-to-month) sit at the same cancellation tier. Read both cancellation policies directly before signing; the on-page summary covers the headline but not the deletion-of-account or refund-window edge cases.
FAQ
Is Hims & Hers cheaper than Medvi?
Can I switch from Hims & Hers to Medvi mid-treatment?
Which program has better member feedback?
Read the full reviews
All head-to-head comparisons → · Full chart → · Cost guide · Programs guide
